UK markets open in 5 hours 7 minutes
NIKKEI 225
38,839.87 +222.77 (+0.58%) HANG SENG
18,998.16 -197.44 (-1.03%) CRUDE OIL
76.86 -0.71 (-0.92%) GOLD FUTURES
2,374.30 -18.60 (-0.78%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,609.70 -453.16 (-0.82%)
Maravai LifeSciences Holdings, Inc. (MAR.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 09:55PM CEST
| Previous close | 10.00 |
| Open | 9.95 |
| Bid | 10.20 x N/A |
| Ask | 10.40 x N/A |
| Day's range | 9.95 - 10.30 |
| 52-week range | 4.20 - 13.60 |
| Volume | |
| Avg. volume | 23 |
| Market cap | 2.566B |
| Beta (5Y monthly) | 0.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.91 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 59.38 |
ZacksMaravai (MRVI) Advances in RNA Research With New Collaboration
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Business WireTriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center
SAN DIEGO, May 13, 2024--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.
Simply Wall St.Maravai LifeSciences Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Maravai LifeSciences Holdings ( NASDAQ:MRVI ) First Quarter 2024 Results Key Financial Results Revenue: US$64.2m (down...
© 2024 Yahoo. All rights reserved.